Objectives: To describe the clinical syndromes of MOGAD at presentation and association of steroid therapy duration with relapse.Methods: All paediatric patients (<16 years of age at time of initial positive anti-MOG antibody testing) in the 2019-2023 period as reported by the West of Scotland Neuroimmunology Laboratory were identified and their medical records retrospectively analyzed.Results: We identified twenty-nine patients with anti-MOG antibodies, twenty-five of whom had MOGAD-related clinical syndromes at first presentation and twenty-two of which were treated with immunosuppression.Of these twenty-two patients 34.5% had acute disseminated encephalomyelitis (mean age 6.8 years at first presentation), 27.5% had optic neuritis (mean age 10.9 years) and 13.8% had transverse myelitis (mean age 9.75 years).The twenty-two MOGAD patients given immunosuppression (IV methylprednisolone for three days in all cases) had an average length of steroid treatment of 47.1 days (range 3--90) and seven patients had a clinical relapse (31%).77.2% of MOGAD patients had magnetic resonance imaging findings consistent with their clinical MOGAD syndromes at initial presentation, and the remainder had unremarkable imaging.Longer duration of initial steroid treatment (>42 days) was found to be associated with no or single relapses, whereas shorter duration (average 24 days) was associated with more than one relapse in those patients who suffered from a relapse.The range of the number of relapses were 0-3 and only one patient had a relapse with a clinically different syndrome to their previous presentation. Conclusions:The majority (75%) of MOGAD patients present with clinical syndromes that are typical of what is understood of the disease process, but some anti-MOG antibodies were seen in patients without MOGAD or in patients with MOGAD-related syndromes that spontaneously improved without immunosuppression.Longer courses of steroids are associated with a lower number of relapses, although further data is required to verify these findings.